Top

Published in:

Open Access 01-01-2020 | Frontotemporal Dementia | Original Communication

Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders

Authors: Kasper Katisko, Antti Cajanus, Olli Jääskeläinen, Aleksi Kontkanen, Päivi Hartikainen, Ville E. Korhonen, Seppo Helisalmi, Annakaisa Haapasalo, Heli Koivumaa-Honkanen, Sanna-Kaisa Herukka, Anne M. Remes, Eino Solje

Published in: Journal of Neurology | Issue 1/2020

Abstract

Due to the significant clinical overlap between frontotemporal lobar degeneration (FTLD) spectrum disorders and late-onset primary psychiatric disorders (PPD), diagnostic biomarkers reflecting the different underlying pathophysiologies are urgently needed. Thus far, elevated cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) have been reported in various neurological conditions. Furthermore, recent advancements in ultrasensitive analytical methods (e.g., single molecule array, Simoa) have enabled sensitive and less invasive NfL detection also from blood samples. In this study, we evaluated the potential of serum NfL (sNfL) as a diagnostic tool between FTLD and PPD. We analyzed sNfL levels with Simoa from 125 participants including patients from FTLD (n = 91) and PPD (n = 34) spectra. Our results show that sNfL levels are higher in the FTLD group compared to the PPD group as well as in separate clinical subtypes of FTLD compared to different psychiatric manifestations (i.e., mood or psychotic disorders). At single-subject level, discrimination between FTLD and PPD was possible with 80% sensitivity and 85% specificity (AUC = 0.850, 95% CI 0.776–0.923), and between behavioral variant frontotemporal dementia (bvFTD) and PPD with 79% sensitivity and 85% specificity (AUC = 0.830, 95% CI 0.732–0.908). These findings highlight the potential of sNfL as a discriminating biomarker for FTLD over PPD in patients with wide-ranging behavioral, psychiatric and cognitive symptoms.

Available only for authorised users

Galimberti D, Dell’Osso B, Altamura AC, Scarpini E (2015) Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. Biol Psychiatry 78:684–692. https://doi.org/10.1016/j.biopsych.2015.03.028 CrossRefPubMed

Solje E, Aaltokallio H, Koivumaa-Honkanen H et al (2015) The phenotype of the C9ORF72 expansion carriers according to revised criteria for bvFTD. PLoS ONE. https://doi.org/10.1371/journal.pone.0131817 CrossRefPubMedPubMedCentral

Woolley JD, Khan BK, Murthy NK et al (2011) The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry 72:126–133. https://doi.org/10.4088/JCP.10m06382oli CrossRefPubMedPubMedCentral

Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577–589. https://doi.org/10.1038/s41582-018-0058-z CrossRefPubMed

Andreasson U, Blennow K, Zetterberg H (2016) Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimer’s Dement Diagn Assess Dis Monit 25(3):98–102. https://doi.org/10.1016/j.dadm.2016.05.005 CrossRef

Al Shweiki M, Steinacker P, Oeckl P et al (2019) Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J Psychiatr Res 113:137–140. https://doi.org/10.1016/j.jpsychires.2019.03.019 CrossRefPubMed

Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014. https://doi.org/10.1212/WNL.0b013e31821103e6 CrossRefPubMedPubMedCentral

Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477. https://doi.org/10.1093/brain/awr179 CrossRefPubMedPubMedCentral

Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554. https://doi.org/10.1212/WNL.51.6.1546 CrossRefPubMed

10.

Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 1(5):293–299. https://doi.org/10.1080/146608200300079536 CrossRef

11.

Rissin DM, Kan CW, Campbell TG et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28:595–599. https://doi.org/10.1038/nbt.1641 CrossRefPubMedPubMedCentral

12.

Vijverberg EGB, Dols A, Krudop WA et al (2017) Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. Alzheimer’s Dement Diagn Assess Dis Monit 7:99–106. https://doi.org/10.1016/j.dadm.2017.01.009 CrossRef

13.

Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655–1661. https://doi.org/10.1515/cclm-2015-1195 CrossRefPubMed

14.

Meeter LH, Dopper EG, Jiskoot LC et al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3(8):623–636. https://doi.org/10.1002/acn3.325 CrossRefPubMedPubMedCentral

15.

Håkansson I, Tisell A, Cassel P et al (2018) Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J Neuroinflammation 15:209. https://doi.org/10.1186/s12974-018-1249-7 CrossRefPubMedPubMedCentral

16.

Steinacker P, Anderl-Straub S, Diehl-Schmid J et al (2018) Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology 91(15):e1390–e1401. https://doi.org/10.1212/WNL.0000000000006318 CrossRefPubMed

17.

Jakobsson J, Bjerke M, Ekman CJ et al (2014) Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients. Neuropsychopharmacology 39(10):2349–2356. https://doi.org/10.1038/npp.2014.81 CrossRefPubMedPubMedCentral

18.

Isgren A, Sellgren C, Ekman CJ et al (2017) Markers of neuroinflammation and neuronal injury in bipolar disorder: relation to prospective clinical outcomes. Brain Behav Immun 65:195–201. https://doi.org/10.1016/j.bbi.2017.05.002 CrossRefPubMed

19.

Mattsson N, Andreasson U, Zetterberg H et al (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 74(5):557–566. https://doi.org/10.1001/jamaneurol.2016.6117 CrossRefPubMedPubMedCentral

20.

Sánchez-Valle R, Heslegrave A, Foiani MS et al (2018) Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease. Alzheimer’s Res Ther 10:113. https://doi.org/10.1186/s13195-018-0439-y CrossRef

21.

Disanto G, Barro C, Benkert P et al (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81(6):857–870. https://doi.org/10.1002/ana.24954 CrossRefPubMedPubMedCentral

22.

Scherling CS, Hall T, Berisha F et al (2014) Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 75(1):116–126. https://doi.org/10.1002/ana.24052 CrossRefPubMedPubMedCentral

23.

Rohrer JD, Woollacott IOC, Dick KM et al (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87(13):1329–1336. https://doi.org/10.1212/WNL.0000000000003154 CrossRefPubMedPubMedCentral

Title: Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders
Authors: Kasper Katisko
Antti Cajanus
Olli Jääskeläinen
Aleksi Kontkanen
Päivi Hartikainen
Ville E. Korhonen
Seppo Helisalmi
Annakaisa Haapasalo
Heli Koivumaa-Honkanen
Sanna-Kaisa Herukka
Anne M. Remes
Eino Solje
Publication date: 01-01-2020
Publisher: Springer Berlin Heidelberg
Keywords: Frontotemporal Dementia
Frontotemporal Dementia
Biomarkers
Published in: Journal of Neurology / Issue 1/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09567-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen

Quantitative nuclear magnetic resonance imaging detects subclinical changes over 1 year in skeletal muscle of GNE myopathy

Chemosensory decrease in different forms of olfactory dysfunction

Treatment of blepharospasm and Meige’s syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice

New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis

Clinical features distinguish cerebral amyloid angiopathy-associated convexity subarachnoid haemorrhage from suspected TIA